To help mitigate this safety risk, prophylactic use of G-CSF is recommended when the risk of febrile neutropenia, determined by considering patient factors and the chemotherapy regimen, is estimated to be approximately 20% [11–13]. This evidence concerns the gene CSF3 and neutropenia.